[First line indications for hormonal therapy in prostate cancer].

Abstract	The utilization of androgen deprivation therapy in prostate cancer has evolved over time. Unquestionably considered first line treatment in metastatic cancers or in case of lymph node involvement, it is increasingly used in locally advanced and high-risk cancers, combined with radiation therapy. However, the practical modalities of treatment are still controversial (neoadjuvant, concomitant/adjuvant) and should be discussed on a case-by-case basis, taking into account tumor stage and risk level, which depends mainly on Gleason score and PSA levels and kinetics. Hormone therapy is also indicated in case of systemic relapse, especially if PSA doubling time is less than 12 months. LHRH agonists have become the standard care; antiandrogens can be added at the beginning of the LHRH agonist therapy to obtain a complete androgen blockade. Intermittent androgen deprivation therapy has recently proved efficacious and might be more widely used in the future, provided that strict prescription and follow-up recommendations are clearly established.
Authors	L Boccon-Gibod, P Richaud, P Coloby, C Coulange, S Culine, J-L Davin, M Soulié, M Zerbib
Journal	Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 20 Issue 2 Pg. 109-15 (Feb 2010) ISSN: 1166-7087 [Print] France
Vernacular Title	Cancer de la prostate et hormonothérapie: indications thérapeutiques de première ligne.
PMID	20142051 (Publication Type: English Abstract, Journal Article)
Copyright	(c) 2009 Elsevier Masson SAS. All rights reserved.
Chemical References	Androgen Antagonists Gonadotropin-Releasing Hormone Prostate-Specific Antigen
Topics	Androgen Antagonists (therapeutic use) Combined Modality Therapy Follow-Up Studies Gonadotropin-Releasing Hormone (agonists) Humans Lymphatic Metastasis Male Neoplasm Staging Prostate-Specific Antigen (blood) Prostatectomy Prostatic Neoplasms (drug therapy, mortality, pathology, radiotherapy, surgery) Survival Rate Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!